NASDAQ · Biotechnology

Harpoon Therapeutics, Inc. (HARP) Stock

$23.01 +0.09% NASDAQ: HARP Healthcare

Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators.

Valuation

MetricValue
Price$23.01
Market Cap$865.08M
P/E Ratio-1.14
P/B Ratio14.14
P/S Ratio27.11
EPS (TTM)$-20.24
52-Week High$23.21
52-Week Low$3.11
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-211.56%
ROA-91.06%
ROCE-320.83%
Gross Margin90.30%
Operating Margin-214.08%
Net Margin-210.36%
Debt/Equity2.96
Current Ratio1.04

Annual Financials (USD)

Metric20182019202020212022
Revenue$5.0M$6.0M$17.0M$24.0M$32.0M
Operating Profit$-28.0M$-58.0M$-51.0M$-117.0M$-68.0M
Net Profit$-27.0M$-52.0M$-46.0M$-166.0M$-67.0M
EPS$-11.45$-23.91$-18.52$-51.57$-20.24
Op Margin-583.7%-1007.5%-294.3%-493.6%-214.1%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$103.0M$177.0M$172.0M$155.0M$74.0M
Total Liabilities$156.0M$82.0M$118.0M$97.0M$68.0M
Cash$89.0M$155.0M$21.0M$45.0M$52.0M
Borrowings$0$15.0M$14.0M$12.0M$16.0M

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-27.0M$-3.0M$-9.0M$-122.0M$-89.0M
Investing Cash Flow$-1.0M$-73.0M$-64.0M$34.0M$89.0M
Financing Cash Flow$88.0M$71.0M$5.0M$112.0M$6.0M
Net Cash Flow$61.0M$-1.0M$-68.0M$24.0M$7.0M
Free Cash Flow$-28.0M$-6.0M$-9.0M$-122.0M$-90.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-12.57
FCF Yield-10.35%
Quick Ratio1.04
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALBOAlbireo Pharma, Inc. $44.15 +0.00% -5.61 $915.89M 0.00%
ASLNASLAN Pharmaceuticals Limited $0.60 -14.27% -0.06 $777.12M 0.00%
CBIO $16.84 +2.50% -6.03 $625.50M 0.00%
CDMOAvid Bioservices, Inc. $12.49 +0.00% -5.60 $798.90M 0.00%
CMRXChimerix, Inc. $8.54 +0.00% -8.63 $801.08M 0.00%

About Harpoon Therapeutics, Inc.

Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline. This includes HPN328, currently undergoing Phase I/II clinical trials for small cell lung cancer and tumors that express Delta-like canonical Notch ligand 3; HPN217, also in Phase I/II trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical evaluation for ovarian and pancreatic cancers, alongside other mesothelin-expressing tumors. Furthermore, Harpoon has a preclinical asset, HPN601, aimed at various solid tumor indications. The company has also established a discovery collaboration and licensing agreement with AbbVie Biotechnology Ltd. to develop and market products combining its unique TriTAC technology with soluble T cell receptors. Founded in 2015, Harpoon Therapeutics, Inc. is headquartered in South San Francisco, California.

Harpoon Therapeutics, Inc. is headquartered in US.

Harpoon Therapeutics, Inc. (HARP) stock trades at $23.01 with a market capitalization of $865.08M. The stock is valued at a price-to-earnings (P/E) ratio of -1.14, price-to-book of 14.14, price-to-sales of 27.11. Over the past 52 weeks the stock has ranged between $3.11 and $23.21, and currently trades at its 52-week high.

On profitability, Harpoon Therapeutics, Inc. generates a return on equity (ROE) of -211.56%, return on capital employed of -320.83%, an operating margin of -214.08%, a net profit margin of -210.36%.

Official website: www.harpoontx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides